InvestorsHub Logo
Followers 0
Posts 1533
Boards Moderated 0
Alias Born 05/18/2018

Re: JoniCash post# 13907

Friday, 05/25/2018 9:50:53 AM

Friday, May 25, 2018 9:50:53 AM

Post# of 18649
OXS-3550 for liquid tumors. The TRiKE platform has shown promising in vivo data compared to
BiKEs . (The addition of Il-15 created NK cell proliferation resulting in 60-70% remission vs 30-
50% for BiKE)

OXS-4550 Again using the TRiKE platform In Vivo data isn't yet, however Dr. Miller assured me in
the email that they've made significant progress with it.

OXS-4235 There's a chance (albeit slim) that this Multiple Myeloma drugs enters the clinic this
year
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GTBP News